141 related articles for article (PubMed ID: 36639771)
1. Lower SLC7A2 expression is associated with enhanced multidrug resistance, less immune infiltrates and worse prognosis of NSCLC.
Jiang S; Zou J; Dong J; Shi H; Chen J; Li Y; Duan X; Li W
Cell Commun Signal; 2023 Jan; 21(1):9. PubMed ID: 36639771
[TBL] [Abstract][Full Text] [Related]
2. SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer.
Sun T; Bi F; Liu Z; Yang Q
Aging (Albany NY); 2020 Jul; 12(13):13281-13296. PubMed ID: 32647070
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
4. TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway.
Xing Y; Liu Y; Liu T; Meng Q; Lu H; Liu W; Hu J; Li C; Cao M; Yan S; Huang J; Wang T; Cai L
Cell Commun Signal; 2018 Jul; 16(1):43. PubMed ID: 30064446
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
Wang L; Liu X; Ren Y; Zhang J; Chen J; Zhou W; Guo W; Wang X; Chen H; Li M; Yuan X; Zhang X; Yang J; Wu C
Cell Death Dis; 2017 Apr; 8(4):e2746. PubMed ID: 28406482
[TBL] [Abstract][Full Text] [Related]
6. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
Chen Y; Zhou H; Yang S; Su D
Cell Biochem Funct; 2021 Mar; 39(2):277-286. PubMed ID: 32815556
[TBL] [Abstract][Full Text] [Related]
7. Silencing of X-linked inhibitor of apoptosis decreases resistance to cisplatin and paclitaxel but not gemcitabine in non-small cell lung cancer.
Liu Y; Wu X; Sun Y; Chen F
J Int Med Res; 2011; 39(5):1682-92. PubMed ID: 22117968
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia Induces Multidrug Resistance via Enhancement of Epidermal Growth Factor-Like Domain 7 Expression in Non-Small Lung Cancer Cells.
Shen X; Zhi Q; Wang Y; Li Z; Zhou J; Huang J
Chemotherapy; 2017; 62(3):172-180. PubMed ID: 28351036
[TBL] [Abstract][Full Text] [Related]
10. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
11. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
[TBL] [Abstract][Full Text] [Related]
12. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
13. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of NOLC1 as a potential target for enhancing sensitivity in multidrug resistant non-small cell lung cancer cells.
Huang H; Li T; Chen M; Liu F; Wu H; Wang J; Chen J; Li X
Cell Mol Biol Lett; 2018; 23():54. PubMed ID: 30505321
[TBL] [Abstract][Full Text] [Related]
15. Circular RNA SMARCA5 may serve as a tumor suppressor in non-small cell lung cancer.
Tong S
J Clin Lab Anal; 2020 May; 34(5):e23195. PubMed ID: 31944395
[TBL] [Abstract][Full Text] [Related]
16. GOLM1 predicts poor prognosis of patients with NSCLC and is associated with the proliferation and chemo-sensitivity of cisplatin in NSCLC cells: bioinformatics analysis and laboratory validation.
Zhao M; Li X; Chen X
J Bioenerg Biomembr; 2021 Apr; 53(2):177-189. PubMed ID: 33538941
[TBL] [Abstract][Full Text] [Related]
17. miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC).
Ye J; Zhang Z; Sun L; Fang Y; Xu X; Zhou G
Mol Biosyst; 2016 Oct; 12(11):3417-3424. PubMed ID: 27714074
[TBL] [Abstract][Full Text] [Related]
18. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
He Y; Xie H; Yu P; Jiang S; Wei L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
[TBL] [Abstract][Full Text] [Related]
19. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs).
Liu X; Zhou X; Chen Y; Huang Y; He J; Luo H
Neoplasma; 2020 Jan; 67(1):147-157. PubMed ID: 31686523
[TBL] [Abstract][Full Text] [Related]
20. Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells.
Ma Y; Kang S; Wu X; Han B; Jin Z; Guo Z
Tumori; 2018 Oct; 104(5):338-343. PubMed ID: 28885675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
